Suppliers and packagers for femring

femring

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Millicent Pr	FEMRING	estradiol acetate	INSERT, EXTENDED RELEASE;VAGINAL	021367	NDA	Millicent US, Inc.	72495-201-05	1 POUCH in 1 CARTON (72495-201-05) / 90 d in 1 POUCH	2018-12-10
Millicent Pr	FEMRING	estradiol acetate	INSERT, EXTENDED RELEASE;VAGINAL	021367	NDA	Millicent US, Inc.	72495-202-10	1 POUCH in 1 CARTON (72495-202-10) / 90 d in 1 POUCH	2018-12-10

Suppliers for the Pharmaceutical Drug: Femring

Last updated: July 30, 2025

Introduction

Femring is a prescription vaginal ring designed primarily for hormone replacement therapy (HRT) in menopausal women. It delivers bioidentical estradiol directly to vaginal tissues, effectively alleviating symptoms like vaginal atrophy, dryness, and discomfort. As a niche yet vital pharmaceutical device, Femring's supply chain comprises specialized manufacturers, raw material suppliers, and distribution channels. This analysis examines the key suppliers involved in the production and distribution of Femring, alongside the overarching market dynamics shaping its supply landscape.

Overview of Femring and its Manufacturing Ecosystem

Femring's pharmaceutical formulation hinges on the precise synthesis of estradiol, a natural estrogen, integrated into a silicone-based vaginal ring. The device must meet stringent safety, efficacy, and regulatory standards. Its manufacturing involves multiple critical components:

• Active Pharmaceutical Ingredient (API): Estradiol.
• Device Composition: Medical-grade silicone rubber for the vaginal ring.
• Additional Materials: Lubricants, stabilizers, and packaging materials.

The entire supply chain necessitates high-quality raw materials, rigorous quality control, and compliance with regulatory frameworks, notably the FDA in the United States and EMA in Europe.

Key Suppliers of Raw Materials

1. Estradiol Active Pharmaceutical Ingredient (API) Suppliers

The core active component of Femring, estradiol, is sourced from specialized chemical manufacturers capable of producing pharmaceutical-grade estrogenic compounds under Good Manufacturing Practice (GMP) conditions.

• Synthetically Derived Estradiol Producers:
  Companies such as Watson Pharmaceuticals (now part of Allergan), Geralexis, and Novartis have historically produced GMP-compliant estradiol for pharmaceutical formulations. However, much of the production is highly proprietary, with many API suppliers operating as confidential entities.

• Bulk Chemical Suppliers:
  Entities like BASF, Sigma-Aldrich (Merck), and Mitsubishi Chemical provide raw chemical precursors that can be processed into estradiol, although these are typically intermediates rather than finished APIs.

• Specialized API Manufacturers:
  Smaller firms such as Hetero Labs (India) and Mitsubishi Tanabe Pharma serve as significant API producers, offering high-purity estradiol to pharmaceutical manufacturers globally.

2. Silicone and Polymer Material Suppliers

The silicone rubber forming the ring’s backbone must meet biocompatibility standards.

• Major Suppliers:
  • NuSil Technology: A leader in high-purity silicone materials tailored for medical devices.
  • Dow Corning (Now part of Dow Inc.): Supplies medical-grade silicones used in vaginal ring manufacturing.
  • Wacker Chemie: Provides elastomeric silicone compounds suitable for biomedical applications.

These suppliers ensure silicone materials comply with ISO 10993 standards for biocompatibility.

3. Packaging and Additional Materials Suppliers

High-quality packaging is essential for maintaining product integrity and sterility.

• Pharmaceutical Blister Packaging: Companies like Evonik Industries and Gerresheimer supply sterile, tamper-evident packaging solutions.
• Lubricants and Stabilizers: Suppliers such as AkzoNobel and Clariant provide compatible lubricants approved for medical use.

Manufacturers of Femring

While the formulation and device design are primarily developed by the original innovator, Pfizer Inc. was the initial manufacturer of Femring during its patent lifecycle. Following patent expiration and generic entry, multiple generic manufacturers have entered the market.

Original Manufacturer: Pfizer Inc.

• Production Sites: Pfizer's manufacturing facilities in the United States and Europe, equipped with advanced GMP standards, produced Femring at scale for global distribution.

Generic and Biosimilar Manufacturers

• Post-patent expiration (~2018), several pharmaceutical firms have secured licensing agreements or developed their own versions of estradiol vaginal rings, including:

  • Mylan (now part of Viatris): Developed generic estradiol vaginal ring products.
  • Merck & Co.: Licensed or authorized generic producers.
  • Teva Pharmaceuticals: Entered the market with biosimilar options.
  • Gedeon Richter: Known for women's health products, potentially involved in manufacturing or distribution.

Distribution Channels and Logistics

Distribution of Femring involves a network encompassing:

• Pharmaceutical Distributors: Companies like McKesson and AmerisourceBergen, responsible for warehousing and bulk distribution.
• Specialty Pharmacies: Focused on hormone products, ensuring access for appropriate patient populations.
• Hospital and Clinic Supply Chains: For inpatient and outpatient prescriptions.
• International Exporters: Compliant with regional regulatory frameworks ensuring global availability.

Market Dynamics and Strategic Considerations

Regulatory Environment

The approval and approval maintenance of Femring globally depend on stringent regulations, influencing supply chain stability. Manufacturers must adhere to GMP, ISO standards, and local regulatory approvals, limiting the number of qualified raw material and device suppliers.

Supply Chain Risks and Mitigation

• Material Scarcity: Dependence on specific high-quality silicone and hormone APIs poses risks of supply disruptions.
• Quality Assurance: Suppliers must maintain rigorous testing and validation to meet medical device standards.
• Regulatory Changes: Evolving policies affect manufacturing licenses and trade flows, necessitating agility among suppliers.

Emerging Trends

• Shift Towards Biosimilars: Increased competition from generic and biosimilar estradiol products stabilizes supply but can pressure margins.
• Vertical Integration: Larger pharmaceutical firms are acquiring or developing in-house API production capabilities, reducing reliance on third-party suppliers.
• Innovation in Materials: Development of alternative biocompatible polymers could diversify material supplier dependence.

Key Takeaways

• Dominant raw material suppliers for Femring include specialized API producers (e.g., Hetero Labs, Mitsubishi Chemical) and silicone material providers (e.g., NuSil, Dow Corning).
• Manufacturing of Femring involves a combination of proprietary processes, with Pfizer historically leading, and a growing landscape of generic manufacturers following patent expiration.
• Distribution networks are sophisticated, involving major pharmaceutical wholesalers and specialized pharmacies, with international logistics adapting to regulatory demands.
• Supply chain resilience hinges on securing high-quality raw materials, maintaining compliance, and diversifying supplier bases amid geopolitical and market risks.
• Market competition and technological advancements are shifting product dynamics, fostering innovation and potentially altering supplier relationships.

FAQs

1. Who are the main suppliers of estradiol used in Femring?
Major suppliers include Hetero Labs (India), Mitsubishi Tanabe Pharma, and other GMP-certified manufacturers capable of producing pharmaceutical-grade estradiol. Large chemical companies like BASF and Sigma-Aldrich also provide precursor chemicals used in estradiol synthesis.

2. Which companies produce the silicone materials used in Femring?
NuSil Technology and Dow Corning (Dow Inc.) are primary suppliers of biocompatible silicone elastomers used in vaginal ring manufacturing.

3. Are there alternative suppliers for Femring’s raw materials?
Yes. As patents expire, more manufacturers are entering the space, providing increased sourcing options, though quality standards remain non-negotiable.

4. How does regulatory compliance impact Femring’s supply chain?
Regulatory standards such as GMP and ISO 13485 restrict supplier choices, requiring extensive validation, testing, and certification, thereby impacting supply chain flexibility.

5. What risks could disrupt the supply of Femring?
Risks include raw material shortages, regulatory changes, geopolitical tensions affecting trade, and quality compliance failures, all of which can impede production and distribution.

---

Sources

[1] U.S. Food & Drug Administration (FDA). “Vaginal Ring Drug Products”. FDA.gov.
[2] MarketsandMarkets. “Hormone Replacement Therapy Market”.
[3] Pharma Intelligence. “Global API Market Trends”.
[4] Wacker Chemie. “Medical-Grade Silicone Materials”.
[5] Pfizer Inc. Annual Reports.